Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Blue

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Blood Advances|August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myelomaJennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Blood|June 11, 2026
Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple MyelomaJerald D Noble, Barbara C Peixoto, Meghan A Menges, et al.
Transplantation and Cellular Therapy|July 23, 2023
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR AnalysisBrandon J Blue, Ruta Brazauskas, Karen Chen, et al.
Blood Cancer Journal|March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy ConsortiumAndrew J Portuguese, James A Davis, Shahzad Raza, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Blood Advances|August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myelomaJennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Blood|June 11, 2026
Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple MyelomaJerald D Noble, Barbara C Peixoto, Meghan A Menges, et al.
Transplantation and Cellular Therapy|July 23, 2023
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR AnalysisBrandon J Blue, Ruta Brazauskas, Karen Chen, et al.
Blood Cancer Journal|March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy ConsortiumAndrew J Portuguese, James A Davis, Shahzad Raza, et al.
Pageof 6